Meeting
2024 ASCO Breakthrough
Clinical determinants of survival in patients with stage II-III pancreatic cancer.
Authors
Haruka Itakura
Stanford University School of Medicine, Stanford, CA
Haruka Itakura , Qinmei Xu , Diego Toesca , Lucas Vitzthum , Arash Jamalian , Emil Schueler , Emel Alkim , J Richelcyn Baclay , Daniel Tandel Chang , George A. Fisher Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 56)
DOI
10.1200/JCO.2024.42.23_suppl.56
Abstract #
56
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Utility of radiomic features in predicting clinical outcomes in stage II-III pancreatic cancer.
First Author: Haruka Itakura
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Stereotactic body radiotherapy compared to conventionally fractionated radiotherapy for locally advanced or oligometastatic pancreatic cancer.
First Author: Ofri Mizrahi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant SBRT plus regional nodal irradiation with concurrent capecitabine for patients with resectable pancreatic cancer: Survival analysis of prospective phase 1 trial.
First Author: Mustafa Basree
Poster
2023 ASCO Annual Meeting
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
First Author: Richard Tuli